Rifaximin liquid formulations for use inthe treatment of sickle cell disease
AssigneeBausch Health Ireland Limited
InventorsArturo J. Angel, Kasturi R. Pawar, Radhakrishnan S. Pillai
Life of this patent
Estimating the term…
Abstract
Pharmaceutical composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient for use in the treatment of sickle cell disease, vaso-occlusive crises or circulating ages neutrophils.
Claims36
A method of treating sickle cell disease (SCD) in a patient in need thereof comprising administering to the patient a pharmaceutically acceptable composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient.
(canceled)
A method of reducing elevated levels of circulating aged neutrophils (CANs) in a patient in need thereof comprising administering to the patient a pharmaceutically acceptable composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient.
A method of treating vaso-occlusive crises (VOCs) in a patient in need thereof comprising administering to the patient a pharmaceutically acceptable composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient.
(canceled)
8-10. (canceled)
12-14. (canceled)
(canceled)
18-24. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
36-38. (canceled)
40-42. (canceled)
44-49. (canceled)
51-54. (canceled)
60-66. (canceled)
68-88. (canceled)
Dependencies are inferred from the claim text.